{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:18:14Z","timestamp":1788135494564,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Shanghai Municipal Yangpu District Science and Technology Commission and Health Commission Joint Project","award":["YPGWM202303"],"award-info":[{"award-number":["YPGWM202303"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13831-4","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:40:47Z","timestamp":1781768447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Carbapenemase-producing Enterobacterales infections: a real-world cohort study from a secondary hospital in Shanghai, China"],"prefix":"10.1186","volume":"26","author":[{"given":"Wen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"Suppl 1","key":"13831_CR1","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/ofid\/ofy347","volume":"6","author":"M Castanheira","year":"2019","unstructured":"Castanheira M, Deshpande LM, Mendes RE, et al. Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program. Open Forum Infect Dis. 2019;6(Suppl 1):S23\u201333.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"13831_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/jac\/dkq520","volume":"66","author":"P Nordmann","year":"2011","unstructured":"Nordmann P, Poirel L, Toleman MA, et al. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother. 2011;66(4):689\u201392.","journal-title":"J Antimicrob Chemother"},{"key":"13831_CR3","doi-asserted-by":"publisher","first-page":"127249","DOI":"10.1016\/j.micres.2022.127249","volume":"266","author":"J Ma","year":"2023","unstructured":"Ma J, Song X, Li M, et al. Global spread of carbapenem-resistant Enterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy. Microbiol Res. 2023;266:127249.","journal-title":"Microbiol Res"},{"issue":"1","key":"13831_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13756-019-0668-2","volume":"9","author":"L Segagni Lusignani","year":"2020","unstructured":"Segagni Lusignani L, Presterl E, Zatorska B, et al. Infection control and risk factors for acquisition of carbapenemase-producing enterobacteriaceae. A 5 year (2011\u20132016) case-control study. Antimicrob Resist Infect Control. 2020;9(1):18.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"4","key":"13831_CR5","first-page":"463","volume":"22","author":"H Yu","year":"2022","unstructured":"Yu H, Xu X, Li M, et al. Expert consensus statement on laboratory detection and clinical report of carbapenemase among Enterobacterales. Chin J Infect Chemother. 2022;22(4):463\u201374.","journal-title":"Chin J Infect Chemother"},{"issue":"36","key":"13831_CR6","first-page":"2850","volume":"101","author":"Writing Group of the Expert Consensus on the Diagnosis, Treatment, and Prevention of Carbapenem-Resistant Enterobacteriaceae Infections in China, Infectious Diseases Society of China Medical Education Association, C.M.A. Professional Committee on Bacterial Infection and Drug Resistance Prevention and Control","year":"2021","unstructured":"Writing Group of the Expert Consensus on the Diagnosis,Treatment, and Prevention of Carbapenem-Resistant Enterobacteriaceae Infections in China, Infectious Diseases Society of China Medical Education Association, C.M.A. Professional Committee on Bacterial Infection and Drug Resistance Prevention and Control. Expert consensus on the diagnosis, treatment, and prevention of carbapenem-resistant Enterobacteriaceae infections in China. Natl Med J China. 2021;101(36):2850\u201360.","journal-title":"Natl Med J China"},{"key":"13831_CR7","unstructured":"World Health Organization. Ten threats to global health in 2019. 2019. Accessed 29 November 2024 2024. https:\/\/www.who.int\/news-room\/spotlight\/ten-threats-to-global-health-in-2019. Accessed 29 November 2024."},{"key":"13831_CR8","unstructured":"World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. 2017. Accessed 29 November 2024 2024. https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed\/. Accessed 29 November 2024."},{"key":"13831_CR9","doi-asserted-by":"crossref","unstructured":"Gu D, Yan Z, Cai C, et al. Comparison of the NG-test Carba 5, Colloidal Gold Immunoassay (CGI) Test, and Xpert Carba-R for the rapid detection of carbapenemases in carbapenemase-producing organisms. Antibiot (Basel). 2023; 12(2).","DOI":"10.3390\/antibiotics12020300"},{"key":"13831_CR10","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.2147\/IDR.S507692","volume":"18","author":"Y Li","year":"2025","unstructured":"Li Y, Mai Y, Liu Y, et al. Epidemiological Characteristics and Carbapenemase Analysis of Carbapenem-Resistant Enterobacterales Isolates in a Teaching Hospital in Guangzhou, China. Infect Drug Resist. 2025;18:2105\u201317.","journal-title":"Infect Drug Resist"},{"issue":"6","key":"13831_CR11","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1007\/s15010-024-02268-z","volume":"52","author":"I Lopez Montesinos","year":"2024","unstructured":"Lopez Montesinos I, Carot-Coll A, Montero MM, et al. A case-control study of the clinical and economic impact of infections caused by Carbapenemase-producing Enterobacterales (CPE). Infection. 2024;52(6):2241\u201352.","journal-title":"Infection"},{"key":"13831_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fcimb.2020.00314","volume":"10","author":"R Han","year":"2020","unstructured":"Han R, Shi Q, Wu S, et al. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant Enterobacteriaceae Isolated From Adult and Children Patients in China. Front Cell Infect Microbiol. 2020;10:314.","journal-title":"Front Cell Infect Microbiol"},{"issue":"8","key":"13831_CR13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/cid\/ciu1173","volume":"60","author":"MK Hayden","year":"2015","unstructured":"Hayden MK, Lin MY, Lolans K, et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clin Infect Dis. 2015;60(8):1153\u201361.","journal-title":"Clin Infect Dis"},{"key":"13831_CR14","doi-asserted-by":"crossref","unstructured":"van Loon K, Voor In \u2018t Holt AF, Vos MC. A systematic review and meta-analyses of the clinical epidemiology of carbapenem-resistant enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(1).","DOI":"10.1128\/AAC.01730-17"},{"issue":"6","key":"13831_CR15","first-page":"585","volume":"20","author":"Z Yonggui","year":"2020","unstructured":"Yonggui Z, Fupin H, Demei Z, et al. CHINET surveillance of bacterial resistance in secondary care hospitals across China: report of results in 2019. Chin J Infect Chemother. 2020;20(6):585\u201393.","journal-title":"Chin J Infect Chemother"},{"issue":"3","key":"13831_CR16","doi-asserted-by":"publisher","first-page":"236","DOI":"10.15537\/smj.2022.43.3.20210809","volume":"43","author":"SK Vamsi","year":"2022","unstructured":"Vamsi SK, Moorthy RS, Hemiliamma MN, et al. Phenotypic and genotypic detection of carbapenemase production among gram negative bacteria isolated from hospital acquired infections. Saudi Med J. 2022;43(3):236\u201343.","journal-title":"Saudi Med J"},{"issue":"12","key":"13831_CR17","first-page":"1717","volume":"24","author":"China Antimicrobial Resistance Surveillance System","year":"2025","unstructured":"China Antimicrobial Resistance Surveillance System. Antimicrobial resistance of bacteria from different grades of hospitals: surveillance report from China Antimicrobial Resistance Surveillance System, 2020\u20132024. Chin J Infect Control. 2025;24(12):1717\u201334.","journal-title":"Chin J Infect Control"},{"issue":"1","key":"13831_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13054-025-05266-1","volume":"29","author":"G De Pascale","year":"2025","unstructured":"De Pascale G, Cortegiani A, Rinaldi M, et al. Incidence of hospital-acquired infections due to carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa in critically ill patients in Italy: a multicentre prospective cohort study. Crit Care. 2025;29(1):32.","journal-title":"Crit Care"},{"issue":"9","key":"13831_CR19","first-page":"1041","volume":"36","author":"L Guoping","year":"2024","unstructured":"Guoping L, Zhaofei W, Zhen L, et al. Detection and clinical analysis of carbapenemase gene of carbapenem-resistant Enterobacterales. Chin J Microecol. 2024;36(9):1041\u20137.","journal-title":"Chin J Microecol"},{"issue":"7","key":"13831_CR20","first-page":"806","volume":"48","author":"L Zhiwu","year":"2023","unstructured":"Zhiwu L, Tiantian Z, Tengfei X, et al. Analysis of drug resistance and carbapenemase gene of carbapenem-resistant Enterobacteriaceae in a hospital from 2020 to 2021. Chin J Antibiot. 2023;48(7):806\u201312.","journal-title":"Chin J Antibiot"},{"key":"13831_CR21","doi-asserted-by":"crossref","unstructured":"Wang X, Wang Q, Cao B, et al. Retrospective observational study from a chinese network of the impact of combination therapy versus monotherapy on mortality from carbapenem-resistant enterobacteriaceae bacteremia. Antimicrob Agents Chemother. 2019; 63(1).","DOI":"10.1128\/AAC.01511-18"},{"issue":"3","key":"13831_CR22","doi-asserted-by":"publisher","first-page":"e0267021","DOI":"10.1128\/spectrum.02670-21","volume":"10","author":"Q Wang","year":"2022","unstructured":"Wang Q, Jin L, Sun S, et al. Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network. Microbiol Spectr. 2022;10(3):e0267021.","journal-title":"Microbiol Spectr"},{"key":"13831_CR23","unstructured":"CHINET China Antimicrobial Surveillance Network. CHINET 2024 bacterial resistance surveillance report. 2025. Accessed 8 June 2026. http:\/\/www.chinets.com\/Document. Accessed 8 June 2026."},{"issue":"10","key":"13831_CR24","first-page":"1081","volume":"49","author":"L Tingting","year":"2024","unstructured":"Tingting L, Xiaofang X, Hong D. Correlation analysis between carbapenem-resistant Enterobacterales susceptibility phenotypes and carbapenemase enzyme types. Chin J Antibiot. 2024;49(10):1081\u20138.","journal-title":"Chin J Antibiot"},{"issue":"7","key":"13831_CR25","doi-asserted-by":"publisher","first-page":"e0000824","DOI":"10.1128\/spectrum.00008-24","volume":"12","author":"PB Yuan","year":"2024","unstructured":"Yuan PB, Dai LT, Zhang QK, et al. Global emergence of double and multi-carbapenemase producing organisms: epidemiology, clinical significance, and evolutionary benefits on antimicrobial resistance and virulence. Microbiol Spectr. 2024;12(7):e0000824.","journal-title":"Microbiol Spectr"},{"key":"13831_CR26","doi-asserted-by":"crossref","unstructured":"Simon MS, Sfeir MM, Calfee DP, et al. Cost-effectiveness of ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae bacteremia and pneumonia. Antimicrob Agents Chemother. 2019;63(12).","DOI":"10.1128\/AAC.00897-19"},{"issue":"5\u20136","key":"13831_CR27","doi-asserted-by":"publisher","first-page":"106679","DOI":"10.1016\/j.ijantimicag.2022.106679","volume":"60","author":"YL Lee","year":"2022","unstructured":"Lee YL, Ko WC, Hsueh PR. Geographic patterns of global isolates of carbapenem-resistant Klebsiella pneumoniae and the activity of ceftazidime\/avibactam, meropenem\/vaborbactam, and comparators against these isolates: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2020. Int J Antimicrob Agents. 2022;60(5\u20136):106679.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"13831_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/jac\/dkae450","volume":"80","author":"G Bianco","year":"2025","unstructured":"Bianco G, Boattini M, Lupo L, et al. In vitro activity and genomic characterization of KPC-producing Klebsiella pneumoniae clinical blood culture isolates resistant to ceftazidime\/avibactam, meropenem\/vaborbactam, imipenem\/relebactam: an Italian nationwide multicentre observational study (2022-23). J Antimicrob Chemother. 2025;80(2):583\u201392.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"13831_CR29","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1007\/s10096-022-04480-x","volume":"41","author":"G Bianco","year":"2022","unstructured":"Bianco G, Boattini M, Comini S, et al. Implementation of Chromatic Super CAZ\/AVI((R)) medium for active surveillance of ceftazidime-avibactam resistance: preventing the loop from becoming a spiral. Eur J Clin Microbiol Infect Dis. 2022;41(9):1165\u201371.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"13831_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/cid\/ciac268","volume":"75","author":"PD Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum beta-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187\u2013212.","journal-title":"Clin Infect Dis"},{"key":"13831_CR31","doi-asserted-by":"publisher","first-page":"7107","DOI":"10.2147\/IDR.S385240","volume":"15","author":"G Lu","year":"2022","unstructured":"Lu G, Tang H, Xia Z, et al. In vitro and in vivo Antimicrobial Activities of Ceftazidime\/Avibactam Alone or in Combination with Aztreonam Against Carbapenem-Resistant Enterobacterales. Infect Drug Resist. 2022;15:7107\u201316.","journal-title":"Infect Drug Resist"},{"issue":"Suppl 7","key":"13831_CR32","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin Infect Dis. 2019;69(Suppl 7):S565\u201375.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"13831_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1056\/NEJMc1807634","volume":"380","author":"JA McKinnell","year":"2019","unstructured":"McKinnell JA, Dwyer JP, Talbot GH, et al. Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae. N Engl J Med. 2019;380(8):791\u20133.","journal-title":"N Engl J Med"},{"issue":"5","key":"13831_CR34","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10096-025-05080-1","volume":"44","author":"M Boattini","year":"2025","unstructured":"Boattini M, Gaibani P, Comini S, et al. In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-beta-lactamase producers. Eur J Clin Microbiol Infect Dis. 2025;44(5):1041\u201368.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"19","key":"13831_CR35","first-page":"1883","volume":"106","author":"Clinical Microbiology Society of China International Exchange and Promotive Association for Medical and Health Care, Chinese Thoracic Society CMA","year":"2026","unstructured":"Clinical Microbiology Society of China International Exchange and Promotive Association for Medical and Health Care, Chinese Thoracic Society CMA. Expert consensus on microbiological diagnosis, prevention, and treatment of carbapenem-resistant Enterobacterales infections (2026 edition). Natl Med J China. 2026;106(19):1883\u201398.","journal-title":"Natl Med J China"},{"issue":"6","key":"13831_CR36","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1007\/s15010-025-02584-y","volume":"53","author":"Y Dickstein","year":"2025","unstructured":"Dickstein Y, Yahav D, Tiseo G, et al. Carbapenemase type and mortality in blood-stream infections caused by carbapenemase-producing enterobacterales: a multicenter retrospective cohort study. Infection. 2025;53(6):2491\u2013501.","journal-title":"Infection"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13831-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:04:31Z","timestamp":1788134671000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13831-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13831"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13831-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"26 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was an observational cohort study, which was reviewed and determined to be a minimal risk study by the Ethical Review Committee of Shidong Hospital, which approved the study and obtained a waiver of informed consent. This study complies with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1571"}}